All Stories

  1. Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
  2. Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
  3. EEG Frontal Asymmetry in Unipolar and Bipolar Depression
  4. Genome-wide gene expression responses to experimental manipulation of Saccharomyces cerevisiae repressor activator protein 1 (Rap1) expression level
  5. Когнитивная копинг-терапия алкогольной зависимости и невротических расстройств у пациентов с суицидальными мыслями
  6. Serum Growth Factors in Schizophrenia Patients
  7. Incidence Rate of Nicotine Addiction in University Students of Tomsk
  8. Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
  9. Neurospecific Proteins as Transdiagnostic Markers of Affective Disorders
  10. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
  11. Association of Non-Suicidal Self-Harm with Anxiety, Depression and Aggressive Behavior in Young Men of Military Age
  12. Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances
  13. Coherence of the electroencephalogram and peripheral markers of nerve tissue damage in depressive disorders
  14. Disorders of cognitive decision-making mechanisms related to reward in alcohol use disorders
  15. Features of the reward-based decision-making in patients with alcohol use disorders
  16. Structural changes in human brain tissue during prenatal alcoholization at different stages of intrauterine development
  17. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
  18. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
  19. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
  20. https://svpin.org/index.php/menujournal-ru/62-zhurnal-za-2022-god/stati-za-2022-god/489-osobennosti-psikhologicheskogo-reagirovaniya-meditsinskikh-rabotnikov-psikhiatricheskogo-statsionara-na-izmenenie-uslovij-professionalnoj-deyatelnosti-v-stressornoj...
  21. Реабилитация в аддиктивных психотерапевтических сообществах психически больных с коморбидным злоупотреблением синтетическими каннабиноидами
  22. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  23. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  24. The habenular volume and PDE7A allelic polymorphism in major depressive disorder: preliminary findings
  25. Comorbid Mental Disorders and Quality of Life in Patients with Social Phobia
  26. Late Diagnostics of Bipolar Disorder: Impact on Main Characteristics of Disease, Suicidal Behaviour and Social Adaptation Level of Patients
  27. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  28. Факторы риска суицидального поведения при биполярном аффективном расстройстве
  29. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  30. Cytokine Production in Whole Blood Cells Culture of Patients with Alcohol Dependence and Autologous Plasma Oxidative Stress Markers
  31. Психологические факторы, наносящие транснациональный урон общественному психическому здоровью населения в период пандемии
  32. Возможные нейрофизиологические маркеры для дифференциальной диагностики биполярных и униполярных аффективных расстройств
  33. Формирование алкогольной зависимости у женщин тувинской и русской этнической принадлежности
  34. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity
  35. Anxiety level and EEG indicators in alcohol dependence: a model for predicting the duration of therapeutic remission
  36. Cerebral hemodynamics and executive functioning in patients with alcohol use disorders
  37. Cognitive features of patients with bipolar disorder in comorbidity with alcohol use disorders
  38. Current methods for predicting therapeutic response in patients with depressive disorders
  39. Frequency of interictal epileptiform discharges in slow sleep with relapse of tonic-conical seizures in adults with generalized epilepsy after withdrawal of antiepileptic drugs
  40. Quantitative characteristics of the alpha-band of the electroencephalogram in people with alcohol dependence
  41. The differential diagnosis of unipolar and bipolar depression based on EEG signals
  42. A New Paradigm to Indicate Antidepressant Treatments
  43. Quantitative characteristics of the alpha-rhythm of the electroencephalogram in depressive disorders
  44. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  45. P.0007 Concentration of BDNF and NSE in blood serum of patients with alcohol use disorder with and without comorbid mood disorders
  46. P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action
  47. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
  48. Estimation of the effect of lithium salts on cytokine production by blood cells in in vitro experiments
  49. Incidence rate and clinical characteristics of seasonal affective disorders in senior medical students
  50. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  51. Bipolar Disorder: Comorbidity with Other Mental Disorders
  52. Clinical-Dynamical Features of Alcohol Use Disorder and Mood Disorders Considering the Chronology of Their Comorbidity Formation
  53. Показатели иммунитета, тревожность и соматическая патология как факторы формирования затяжного течения панического расстройства
  54. Психическое здоровье семьи: научно-исторический контекст и актуальные исследования томских ученых
  55. Correlation of Antibodies to Neurotransmitters in the Sera of Women with Alcohol Dependence and Depressive Disorders
  56. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  57. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
  58. Влияние исполнительного функционирования на суицидальное поведение при коморбидности алкогольной зависимости и аффективных расстройств
  59. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  60. Clinical characteristics and efficiency of antidepressant therapy of mood disorders with comorbid alcohol use disorder
  61. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
  62. Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
  63. Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness
  64. Mental Disorders Associated with the Abuse of Synthetic Cannabinoids (Spices)
  65. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  66. An innovative anticonvulsant - a GABAA receptor modulator with an alternative mechanism of action and enzyme-inducing detoxifying properties
  67. Biological profile of medical response in alcoholic patients of different ethnic groups in Siberia
  68. Clinical dynamics of anhedonia symptom in mood disorder and in alcohol use disorder
  69. Neuroendocrine factors - predictors of the formation of alcohol dependence and human ecology in various ethnic populations, new approaches to therapy
  70. Психические нарушения, развивающиеся в кризисно-экстремальной ситуации пандемии коронавируса: актуальная проблематика и особенности психолого-психотерапевтического консультирования
  71. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  72. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia
  73. An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism
  74. Features of brain activity in alcohol dependence in the task of inhibitory control
  75. Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
  76. ALCOHOL DEPENDENCE OCCURRENCE AND COGNITIVE COPING PREVENTIONIN STUDENTS AND YOUNG SPECIALISTS
  77. Cognitive impairment in patients after COVID-19
  78. DYNAMICS OF THE PSYCHOPATOLOGICAL PICTURE OF PSYCHOSIS DEVELOPED IN THE BACKGROUND OF THE CONSUMPTION OF MODERN SYNTHETIC PSYCHOACTIVE SUBSTANCES
  79. Normative Assessment of Cognitive Functions with on the Brief Assessment of Cognition In Schizophrenia (BACS) Scale in the Tomsk Population: Constitutional Factors of Variability
  80. Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders
  81. Possible clinical and electroencephalographic factors for predicting the duration of remission in patients with alcohol dependence
  82. SPATIAL DISTRIBUTION OF BIOPOTENTIALS AND THEIR SOURCES IN BRAIN STRUCTURES IN alcohol-dependent patients WITH COMORBID AFFECTIVE DISORDER
  83. Влияние когнитивных функций на уровень суицидального риска у больных шизофренией
  84. Using the quantitative EEG method in predicting the response to treatment of affective disorders
  85. Взаимосвязь цифровых маркеров онлайн-активности и социально-демографических характеристик лиц призывного возраста с несуицидальными формами самоповреждающего поведения
  86. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum
  87. P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients
  88. P.552 Acylcarnitine levels in paranoid schizophrenia with metabolic syndrome during treatment of second-generation antipsychotics
  89. P.514 Contribution of polymorphic variants of MAO genes into prolactin levels in patients with schizophrenia under risperidone therapy
  90. P.182 Metabolic syndrome in patients with schizophrenia and the PTPN5 gene encoding the striatal-enriched protein tyrosine phosphatase
  91. P.513 Metabolic syndrome in schizophrenia and polymorphic variants of CYP1A2 and GSTP1 genes
  92. P.170 Polymorphisms of serotonergic system genes and their association with remission in patients with depression
  93. P.235 S-100, MBP and glial fibrillary acidic protein (GFAP) in patients with mood disorders and alcohol use disorder
  94. P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia
  95. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  96. Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
  97. Genetic polymorphisms of PIP5K2A and course of schizophrenia
  98. Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders
  99. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  100. Психологические факторы формирования суицидального поведения при обсессивно-компульсивном и социальном тревожном расстройстве
  101. Формирование суицидальности у молодых пациентов с аддиктивными и невротическими расстройствами: социально-психологические факторы риска и психотерапия
  102. NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
  103. Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
  104. Обзор исследований несуицидальных форм самоповреждений по шкалам и опросникам NSSI
  105. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  106. 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
  107. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
  108. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients
  109. Correction to: Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  110. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
  111. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
  112. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  113. Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  114. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  115. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  116. Clinical value of comorbidity of affective disorders and alcohol dependence
  117. Incidence rate of anxiety and personality disorders and their interrelationship in senior-year students of the medical university
  118. Magnetic resonance spectroscopy in Parkinson’s disease
  119. Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
  120. Hormones of stress-response system in alcohol dependence: the ability to predict duration of remission
  121. Relationship of cognitive disorders with clinical features of alcohol dependence
  122. Therapy of patients with breast cancer with anxiety and depressive disorders
  123. WITHDRAWAL SYNDROME IN SYNTHETIC CANNABINOID DEPENDENCE ASSOCIATED WITH MENTAL DISORDERS
  124. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  125. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  126. P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome
  127. P.505 The potential role of BDNF and prolactin genotypes on antidepressant response in depressive patients
  128. P.072 Proteomic approach in schizophrenia and bipolar disorder
  129. P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia
  130. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  131. Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
  132. Доля наркозависимых среди завершённых суицидов
  133. Суицидальное поведение больных шизофренией с метаболическим синдромом
  134. Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps
  135. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  136. The difference in serum proteomes in schizophrenia and bipolar disorder
  137. Protective Effects of Pyruvic Acid Salt Against Lithium Toxicity and Oxidative Damage in Human Blood Mononuclear Cells
  138. Суицидальное и парасуицидальное рискованное поведение среди высокообразованной молодежи: дихотомия формирования и дифференцированные возможности когнитивно-поведенческой копинг-терапии
  139. Суицидальные действия наркозависимых: вопросы системного выявления и учёта
  140. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  141. The Protective Action of Carnosine and Organic Lithium Salts against Ethanol-Induced Oxidative Damage of Blood Plasma Proteins and Lipids of Healthy Persons and Alcoholic Patients
  142. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  143. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  144. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  145. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  146. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  147. Protective action of carnosine and organic lithium salts in case of ethanol-induced oxidative damage of proteins and lipids of blood plasma in healthy persons and alcoholic patients
  148. Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia
  149. Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders
  150. Brain pathology in schizophrenia: association with clinical and constitutional factors
  151. DEVELOPMENT OF ADDICTIVE BEHAVIOR IN ADOLESCENT FEMALE STUDENTS FROM COMPREHENSIVE AND CORRECTIVE BOARDING SCHOOLS
  152. Effects of antipsychotic therapy on lipid and carbohydrate metabolism of schizophrenic patients
  153. NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT
  154. Parameters of immunity and level of cortisol in schizophrenic patients under long-term therapy with risperidone
  155. Prediction of visceral obesity in schizophrenic patients under therapy with antipsychotics
  156. Quantitative assessment of gray matter changes in patients with schizophrenia by MRI approach
  157. Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature
  158. The role of neuroendocrine factors in the formation of alcohol dependence and human ecology in different ethnic populations: new approaches in therapy
  159. Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft
  160. Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
  161. Связь суицидального поведения и безнадёжности с акатизией у больных шизофренией
  162. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  163. Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy
  164. IgG antibodies from the sera of patients degrade myelin basic protein
  165. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  166. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  167. Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)
  168. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  169. Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy
  170. Inflammatory factors and immunophenotypes in adjustment disorders
  171. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  172. Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia
  173. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum
  174. Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia
  175. Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders
  176. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  177. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
  178. Olfaction, pain sensitivity and immunoendocrine system in substance use disorders
  179. THE BEHAVIOR STRATEGIES IN SITUATIONS OF DISORDER AND MEASURES CONTRIBUTING HEALTH CONDITIONS OF PATIENTS WITH MENTAL ILNESSES COMBINED WITH COMORBID DEPRESSION SYNDROME
  180. Clinical-immunological predictors of prognosis of the efficiency of antipsychotic therapy with amisulpride in schizophrenia
  181. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  182. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  183. Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia
  184. Biomarkers of depressive disorders: A multiplex analysis of blood serum
  185. Clinical Variants of Psychopathological Disorders in Users of Synthetic Cannabinoids (Spices)
  186. Effect of original anticonvulsant meta-chloro-benzhydryl-urea on behavioral and immune parameters in mice with active and passive behavior types in experimental alcoholism
  187. Effect of Prenatal Exposure to Alcohol on the Development of Brain Vessels in Human Embryos and Fetuses
  188. Evaluation of dynamics of neurocognitive indicators and pathological craving in patients with dependence on synthetic cannabinoids during use of microwave resonance therapy
  189. Factors of premorbid period indicating the risk of medicated noncompliance in patients with schizophrenia
  190. Molecular targets of the ethanol and original anticonvulsant in the treatment of alcohol dependence
  191. Morphophenotypical patterns in patients with negative symptoms in schizophrenia
  192. Women with hysterical manifestations: Menopause, gender and mental health
  193. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  194. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  195. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  196. Gender aspects of medico-social adaptation in adults with early onset of epilepsy
  197. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  198. Association of СОМТ gene polymorphisms with Parkinson’s disease
  199. Нейрогуморальные маркеры прогноза эффективности фармакотерапии депрессивных расстройств, "Нейрохимия"
  200. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  201. Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia
  202. Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients
  203. Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia
  204. CYP2D6 and catechol-O-methyltransferase gene polymorphisms in Parkinson patients with levodopa-induced dyskinesias
  205. Dynamics of neurohumoral factors in patients with depressive disorders in the treatment with selective serotonin reuptake inhibitors
  206. Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia
  207. Neurohormonal factors of atypical depression
  208. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  209. FEATURES OF COGNITIVE RESOURCES OF COPING WITH DIFFICULT LIFE SITUATIONS IN REPRESENTATIVES OF ETHNIC GROUPS OF SIBERIA
  210. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group
  211. Agression of adolescents who comnmit offenses
  212. Cognitive functioning in alcoholic patients and efficiency of their correction with use of individualized therapy
  213. Therapeutic efficacy of original anticonvulsant meta-chloro-benzhydrylurea (m-ch-BHU) in the treatment of patients with a compulsive craving for alcohol
  214. not-labeling of psychiatry and mental patients
  215. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  216. Disrupted homeostasis during chronic ethanol consumption associated with specific mechanism of endogenous neurosteroids activity
  217. Neuroleptic effect in aggressive mice after the transplantation of immune cells treated in vitro with chlorpromazine
  218. Russian Federation
  219. Antioxidant and Immunotropic Properties of some Lithium Salts
  220. Treatment of Alcoholic Patients Using Anticonvulsant Urea Derivative Influences the Metabolism of Neuro-active Steroid Hormones - The System of Stress Markers
  221. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  222. The Effect of Chronic Alcohol Abuse on the Benzodiazepine Receptor System in Various Areas of the Human Brain
  223. An effect of quetiapine on the immune system of patients with schizophrenia
  224. PSYCHOMETRIC EVALUATION OF SYMPTOMS AND CLINICAL DYNAMICS OF SCHIZOPHRENIA IN DEPENDING ON CONSTITUTIONALLY-MORPHOLOGICAL TYPE OF THE PATIENTS
  225. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  226. The association of the DRD3 gene with Parkinson’s disease
  227. The Influence of Alcohol Addiction on Cognitive Functions of the Representatives of Indigenous Population of Siberia
  228. An association of AKT1 gene polymorphism with antidepressant treatment response
  229. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  230. Association of Cytokine Production with Hormone Level and Sensory Responses during the Formation of Psychoactive Drug Addiction in Men
  231. Association of drd3 gene polymorphisms with parkinson's disease (PD)
  232. Влияние адамантилбромфениламина на параметры иммунитета и симптомы астении у пациентов с непсихотическими психическими расстройствами
  233. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  234. P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia
  235. P.5.d.005 Polymorphisms of DRD2, DRD3, DRD4 and HTR2C genes in levodopa-induced dyskinesias in Parkinson's disease
  236. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  237. Ethnoterritorial Heterogeneity of Formation of Alcohol Dependence in Native Population of Siberia
  238. Cytochrome P450 System Activity in Alcoholic Patients From Different Ethnic Groups
  239. Brain-derived Neurotrophic Factor in Patients with Affective Disorders
  240. Use of Traditional and Atypical Neuroleptics in Therapy of Psychoses Caused by Use of Synthetic Drugs
  241. Serum Levels of Neurosteroids in Patients with Affective Disorders
  242. New Approaches to the Treatment Alcohol Addiction in Experimental Alcoholism
  243. Role of Benzodiazepine Receptor Plasticity Associated with Neuroactive Steroid's Levels in Patients with Compulsive Craving for Alcohol, New Approaches to Therapy
  244. CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
  245. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  246. Analysis of alcohol dependence in indigenous peoples in Northern Siberia.
  247. Association between pathological olfaction, immunological abnormalities and predisposition to substance use
  248. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  249. P.2.a.008 Correlation between levels of Akt1/GSK-3β signaling pathway proteins and severity of depressive symptoms
  250. P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde
  251. P.1.g.051 Benzodiazepine receptor system in the brains of rats with experimental alcoholism and treatment effect of a novel anticonvulsant
  252. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  253. Ratio of Antibodies to Neurotransmitters in the Serum of Students, Occasional Drug Users
  254. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  255. Effect of Meta-Chlorobenzhydryl Urea (m-ClBHU) on Benzodiazepine Receptor System in Rat Brain During Experimental Alcoholism
  256. Neurophysiological Patterns of Search and Creative Behavior in Patients with Psychoactive Substance-Induced Disorders
  257. Glutamate Concentration in the Serum of Patients with Schizophrenia
  258. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  259. P.6.a.005 Density of thrombocyte benzodiazepine receptors and levels of neuroactive steroid hormones in alcoholic patients
  260. Features of EEG in patients with disorders due to psychoactive substance use during olfactory stimulation
  261. Psychological Defense and Strategies of Coping in Alcohol Dependence and Co-Dependence in Women
  262. 1579 – Migration and mental health of aborigines of siberia: new challenges of old problems
  263. 1581 – Steroid hormones levels in alcohol dependent patients under conditions of social isolation
  264. 491 – Efficacy of original anticonvulsant galodif in treating of patients with compulsive craving to alcohol, associated with alteration levels of steroid hormons
  265. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  266. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  267. P.6.a.006 A new original anticonvulsant decreases alcohol motivation and alters progesterone level in plasma of alcoholic patients
  268. P-14 - Dissociative mechanisms of formation of alcoholism in patients with co-morbid posttraumatic stress disorder
  269. Gender Heteronomy of the Formation of Heroin Addiction in Adolescents
  270. P.6.b.007 Influence of ethanol on synaptic benzodiazepine receptors and forming synapses in embryo's brain of alcoholic women
  271. P.6.b.006 Pharmacokinetic peculiarities of antipirine during treatment of alcoholic patients
  272. P.6.008 Neuropeptide in treatment of alcoholism: effect on psychological functions and lymphocyte apoptosis
  273. Influence of original anticonvulsant on pharmacometabolizing function of liver in patients with alcoholism
  274. P01-12 - Clinical prognosis of associated forms of alcoholism with co-morbid brain impairment
  275. P01-106 - Neuromorphologic and neurochemical regularities of prenatal exposure of developing human brain to alcohol
  276. P.6.a.007 Influence of neuroactive peptidic preparations on apoptosis of immunocompetent cells in alcoholic patients
  277. P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients
  278. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  279. P02-80 - Steroid hormones in patients with personality disorders in conditions of social isolation
  280. PW01-218 - Apoptosis of lymphocytes in alcoholic patients during withdrawal syndrome therapy
  281. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  282. P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy
  283. P.6.b.006 Peripheral benzodiazepine receptor in platelets of alcoholic patients as a test of efficacy of antialcohol drugs
  284. Effects of Microwave Resonance Therapy on Erythrocyte and Plasma Proteins and Lipids in Alcoholics
  285. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  286. P.6.d.012 Immune system in opioid addicts
  287. P.3.d.011 Immunotropic effects of atypical neuroleptics olanzapine and amisulpride
  288. P.6.b.003 Anticraving-therapy of alcoholism in patients with comorbid arterial hypertension: abilities of paroxetine
  289. P.3.c.044 Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients
  290. P.6.b.008 Treatment of alcoholic patients with original anticonvulsant alters alcohol motivation and progesterone level in plasma
  291. Gender-associated patterns of heroin addiction in adolescents
  292. Anticonvulsive properties of M-chlorbenzhydrilurea and prospect of its clinical application
  293. Kinetic of a new drug in patients with alcoholism
  294. The influence of the Antioxidant Carnosin on the intensity of the alcoholic patients pathological addiction to alcohol during rehabilitation period
  295. P.1.b.003 Anticonvulsive drug kinetic in patients with alcoholism
  296. Comorbidity and therapy of affective disturbances in associated forms of alcoholism
  297. Erythrocyte and plasma protein modification in alcoholism: A possible role of acetaldehyde
  298. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity
  299. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  300. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  301. P.6.032 Pica, anxiety and addiction: Mechanismsand therapy
  302. P.6.064 Influence of alcohol dependence on oxidative metabolism of xenobiotics in humans
  303. Effect of carnosine on immunocompetent cells from alcoholic patients
  304. Immunity system in alcoholism
  305. COMORBIDITY OF AFFECTIVE DISTURBANCES IN ASSOCIATED FORMS OF ALCOHOLISM.
  306. Effects of antioxidant carnosine on immunity in addiction
  307. IN VITRO EFFECTS OF ETHANOL, ACETALDEHYDE AND FATTY ACID ETHYL ESTERS ON HUMAN ERYTHROCYTES
  308. Therapeutic efficiency coaxil at treatment of alcoholism
  309. EFFECTS OF CARNOSINE AND RELATED COMPOUNDS ON THE STABILITY AND MORPHOLOGY OF ERYTHROCYTES FROM ALCOHOLICS
  310. Efficacy of finlepsin-retard by alcoholism with comorbld brain impairment
  311. Olfaction, nociception and immunity in mental disorders
  312. Sensory systems and immunity in mental disorders